What is Catalent?
Catalent operates as a premier Contract Development and Manufacturing Organization (CDMO), providing essential infrastructure for the pharmaceutical, biotech, and consumer health industries. The company is uniquely positioned to facilitate the entire product journey, from early-stage development and clinical trials to full-scale commercial manufacturing. Its core competencies include advanced delivery technologies, specialized manufacturing processes, and comprehensive supply chain solutions. By acting as a strategic partner to global health entities, Catalent enables the rapid deployment of innovative therapies, ranging from complex biologics to essential consumer health brand extensions. Its market authority is derived from a deep-scale expertise that bridges the gap between laboratory innovation and patient access, making it an indispensable node in the global healthcare ecosystem.
How much funding has Catalent raised?
Catalent has raised a total of $5.2B across 9 funding rounds:
Stock Offering
$870M
Debt
$410.1M
Stock Offering
$24.2M
Debt
$450M
Stock Offering
$387M
Debt
$1.2B
Debt
$500M
Stock Offering
$500M
Debt
$903.4M
Stock Issuance/Offering (2014): $870M with participation from Undisclosed
Debt (2016): $410.1M led by Undisclosed
Stock Issuance/Offering (2017): $24.2M supported by BofA Merrill Lynch, RBC Capital Markets, JPMorgan Chase, and Morgan Stanley
Debt (2017): $450M featuring Undisclosed
Stock Issuance/Offering (2018): $387M backed by JPMorgan Chase, Morgan Stanley, Wells Fargo Securities, BofA Merrill Lynch, and RBC Capital Markets
Debt (2019): $1.2B with participation from JPMorgan Chase Bank
Debt (2019): $500M led by Undisclosed
Stock Issuance/Offering (2020): $500M supported by JPMorgan Chase and UBS Investment Bank
Debt (2020): $903.4M featuring Undisclosed
Key Investors in Catalent
JPMorgan Chase
A leading global financial services firm providing comprehensive investment banking, asset management, and commercial banking solutions to institutional and corporate clients.
Morgan Stanley
A global financial services leader specializing in investment banking, securities, and wealth management for corporations, governments, and institutional investors.
BofA Merrill Lynch
A major global financial institution offering a broad spectrum of banking, capital markets, and wealth management services to diverse institutional and corporate entities.
What's next for Catalent?
Looking ahead, Catalent is poised to leverage its recent capital infusion to further enhance its manufacturing footprint and technological infrastructure. The strategic focus remains on scaling capacity for high-demand modalities, including cell and gene therapies, which represent the next frontier in personalized medicine. As the company continues to integrate advanced digital platforms into its supply chain, it is expected to drive greater efficiencies for its global partners. The ongoing support from top-tier financial institutions provides the necessary liquidity to pursue both organic growth initiatives and potential strategic acquisitions, ensuring that Catalent remains at the forefront of the CDMO sector. Investors and industry stakeholders will likely monitor the firm's ability to maintain its operational excellence while navigating the evolving regulatory and technological requirements of the global pharmaceutical market.
See full Catalent company page
